Slide 1: 2012 First nine months' results
2012 First nine months’ results 25 OCTOBER 2012
Slide 2: First nine months 2012 highlights
First nine months 2012 highlights • Revenue € 620.3 million, up 6.8%. • Operating income (EBIT) € 132.4 million or 21.3% of sales, up 2.7%. • Net income € 93.1 million or 15.0% of sales, up 1.2%. • Phase III trials started for REC 0482, the new innovative BPH treatment from Nymox • Acquisition of 6
Slide 3: Main product sales
Main product sales Corporate products including orphan drugs now account for 43.6% of revenue (million Euro) Jan‐Sep 2012 Jan‐Sep 2011 Change % Zanidip® (lercanidipine) 91.4 98.0 (6.8) Zanipress® (lercanidipine+enalapril) 36.5 30.9 18.1 Urorec® (silodosin) 22.9 12.8 79,4 Livazo® (pitavastatin) 12.3
Slide 4: A richer product portfolio
A richer product portfolio Urorec 3.7% Livazo 2.0% Other corporate products 8.1% Zanipress 5.9% Orphan drugs 9.2% Zanidip 14.7% Pharmaceutical chemicals 3.6% Subsidiaries’ local product Other revenue 1.6% portfolios 51.2% Entact®/Elopram® 5% (escitalopram/citalopram) ‐ Italy Tergynan® ‐ Russia & CIS
Slide 5: Composition of revenue
Composition of revenue New markets and new products drive growth (million Euro) Jan‐Sep 2012 Jan‐Sep 2011 Change % Italy 162.7 168.5 (3.5) France 89.8 96.8 (7.2) Germany 51.4 49.4 4.1 Turkey 48.1 20.9 130.1 Spain 25.4 23.3 8.9 Portugal 24.9 25.8 (3.5) United Kingdom 5.2 5.8 (10.7) Other Western Euro
Slide 6: A growing presence in Eastern Europe and Turkey
A growing presence in Eastern Europe and Turkey Spain 4.2% Portugal 4.2% Turkey 8,0% UK 0.9% Germany 8.6% Other W. European countries 2.5% Russia, other CEE 8.8% France 15.0% Other international sales 20.6% (sales to licensees and exports) Italy 27,2% Data: First nine months 2012 Pharmaceutical reve
Slide 7: First nine months 2012 results
First nine months 2012 results Sales and earnings growth in line with guidance (million Euro) Jan‐Sep 2012 Jan‐Sep 2011 Change % Revenue 620.3 580.6 6.8 Gross Profit 401.6 383.8 4.6 as % of revenue 64.7 66.1 SG&A Expenses 221.2 208.2 6.3 as % of revenue 35.6 35.8 R&D Expenses 44.5 44.0 1.1 as % of r
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 30 Sep 2012 31 Dec 2011 Change Cash and short‐term financial 106.5 105.2 1.3 investments Bank overdrafts and short‐term loans (11.0) (13.6) 2.6 Loans – due within one year (8.2) (11.6) 3.4 Loans – due after one year (131.9) (135.7) 3.8 NET F
Slide 9: Financial projections
Financial projections Challenging 2012 targets 2011 2012 (million Euro) Actual Targets Revenue 762.0 810‐830 Operating income (EBIT) 163.5 160‐170 Net Income 116.4 115‐120 9
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finan